PointState Capital’s Zimmer Biomet ZBH Stock Holding History

PointState Capital’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,300	Closed	-$1.19M	–	133
2020 Q2	$1.19M	Buy	+10,300	New	+$1.19M	0.04%	80

Other funds holding ZBH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PointState Capital's ZBH Position: Q1 2022 in Review

PointState Capital sold out of Zimmer Biomet (ZBH) in Q1 2022, closing a stake of 51,500 shares — an estimated $6.35M sold.

PointState Capital first reported a position in ZBH in Q1 2018 and held it in 8 quarters. The position peaked at $56M in Q1 2018. 977 funds tracked by Wall St. Rank hold ZBH as of Q1 2022.

PointState Capital reported no remaining Zimmer Biomet position as of Q1 2022 after selling out during the quarter.
PointState Capital sold 51,500 Zimmer Biomet shares in Q1 2022, an estimated $6.35M.
PointState Capital first reported a position in Zimmer Biomet in Q1 2018 and held it in 8 quarters.
PointState Capital's Zimmer Biomet position peaked at $56M in Q1 2018.
977 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.